Olga V. Boulashova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olga V. Boulashova has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Khazova
Kazan State Medical University
13 shared publications - Elena V. Valeeva
Kazan State Medical University, Ministry of Health of the Russian Federation
3 shared publications - Elza I. Mukhitova
M.N. Sadykov City Clinical Hospital no 7
3 shared publications - Maria I . Malkova
Kazan State Medical University; Sadykov City Clinical Hospital № 7
2 shared publications - Aigul R. Murzakova
Kazan State Medical University
1 shared publication - Alla A. Podolskaya
Kazan State Medical University
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (5) , 700-710
Serotonergic dysregulation: a path to early diagnosis of cardiorenal syndrome
Cardiorenal syndrome remains one of the most complex and unresolved challenges in modern clinical medicine, associated with high mortality, frequent complications, and an unfavorable long-term prognosis for patients. Existing clinical guidelines do not solve the main problem: the biomarkers currently used in routine practice—serum creatinine, estimated glomerular filtration rate, and natriuretic peptides—respond to already established organ damage, predominantly of a single organ, or reflect systemic pathology as a whole, but they do not allow detection of preclinical shifts in inter-organ regulation at early stages. In this context, serotonin (5-hydroxytryptamine, 5-HT) is considered a promising integrative biomarker potentially capable of filling the existing diagnostic niche. To analyze current data on peripheral 5-HT metabolism, its active involvement in endothelial dysfunction, platelet-dependent inflammation, myocardial and renal tissue remodeling, and atherogenesis, 39 full-text publications (2000–2025) were selected from eLibrary.Ru and PubMed using the keywords “серотонин” (serotonin), “хроническая сердечная недостаточность” (chronic heart failure), and “хроническая болезнь почек” (chronic kidney disease). Special attention in this review is given to the phenomenon of opposite-directional changes in 5-HT levels in chronic heart failure and chronic kidney disease—an apparent contradiction that, on closer examination, becomes a potentially valuable diagnostic resource. Serotonin itself, its specific receptors, and major metabolites (5-HIAA, SERT, 5-HT1B/2A/2B/4 receptors) are discussed as candidates for the role of early markers of cardiorenal syndrome. At the same time, the current evidence base remains fragmentary: prospective studies assessing serotonin dynamics at different stages of cardiorenal syndrome are lacking, clinical reference intervals have not been defined, and the comparative informative value of plasma and platelet pools has not been investigated. Further validation of serotonin as a biomarker and study of the possibilities of pharmacological modulation of its receptors may open new approaches to early diagnosis and pathogenetic therapy of cardiorenal syndrome.
- 9 October 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (5) , 700-710
Open AccessSerotonergic dysregulation: a path to early diagnosis of cardiorenal syndrome
Cardiorenal syndrome remains one of the most complex and unresolved challenges in modern clinical medicine, associated with high mortality, frequent complications, and an unfavorable long-term prognosis for patients. Existing clinical guidelines do not solve the main problem: the biomarkers currently used in routine practice—serum creatinine, estimated glomerular filtration rate, and natriuretic peptides—respond to already established organ damage, predominantly of a single organ, or reflect systemic pathology as a whole, but they do not allow detection of preclinical shifts in inter-organ regulation at early stages. In this context, serotonin (5-hydroxytryptamine, 5-HT) is considered a promising integrative biomarker potentially capable of filling the existing diagnostic niche. To analyze current data on peripheral 5-HT metabolism, its active involvement in endothelial dysfunction, platelet-dependent inflammation, myocardial and renal tissue remodeling, and atherogenesis, 39 full-text publications (2000–2025) were selected from eLibrary.Ru and PubMed using the keywords “серотонин” (serotonin), “хроническая сердечная недостаточность” (chronic heart failure), and “хроническая болезнь почек” (chronic kidney disease). Special attention in this review is given to the phenomenon of opposite-directional changes in 5-HT levels in chronic heart failure and chronic kidney disease—an apparent contradiction that, on closer examination, becomes a potentially valuable diagnostic resource. Serotonin itself, its specific receptors, and major metabolites (5-HIAA, SERT, 5-HT1B/2A/2B/4 receptors) are discussed as candidates for the role of early markers of cardiorenal syndrome. At the same time, the current evidence base remains fragmentary: prospective studies assessing serotonin dynamics at different stages of cardiorenal syndrome are lacking, clinical reference intervals have not been defined, and the comparative informative value of plasma and platelet pools has not been investigated. Further validation of serotonin as a biomarker and study of the possibilities of pharmacological modulation of its receptors may open new approaches to early diagnosis and pathogenetic therapy of cardiorenal syndrome.
- Open Access
- 13 March 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (2) , 241-250
Autonomic nervous system in chronic heart failure
The autonomic nervous system is a critical regulator of cardiovascular function, and its imbalance contributes substantially to cardiovascular diseases and their complications. This work aimed to analyze studies addressing the impact of the autonomic nervous system on the course and prognosis of chronic heart failure, including in patients with comorbidities. The review included 47 papers published between 2000 and 2025 in PubMed and eLIBRARY.RU journals that investigated the role of the autonomic nervous system in chronic heart failure. The article discusses the origins of heart rate variability assessment and diagnostic tools for evaluating autonomic nervous system function in various cardiovascular diseases. The review describes the pathogenetic mechanisms underlying changes in autonomic status and the key parameters used to assess it, predominantly based on noninvasive time- and frequency-domain heart rate variability analysis for a more accurate evaluation of adaptation level, stress reactivity, and the degree of autonomic imbalance. Data on age- and sex-related differences in heart rate variability in patients with chronic heart failure are presented, including those with comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, and diabetes mellitus. Evidence is provided to support the prognostic value of heart rate variability parameters that influence disease course and cardiovascular risk in patients with chronic heart failure. Investigating the pathogenetic mechanisms underlying autonomic dysfunction in patients with cardiovascular diseases is relevant for developing new therapeutic approaches to restore autonomic nervous system balance. Time- and frequency-domain heart rate variability analysis is an accessible and convenient noninvasive method that can be used in a wide patient population to provide valuable information for personalized therapeutic strategies.
- 13 March 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (2) , 241-250
Open AccessAutonomic nervous system in chronic heart failure
The autonomic nervous system is a critical regulator of cardiovascular function, and its imbalance contributes substantially to cardiovascular diseases and their complications. This work aimed to analyze studies addressing the impact of the autonomic nervous system on the course and prognosis of chronic heart failure, including in patients with comorbidities. The review included 47 papers published between 2000 and 2025 in PubMed and eLIBRARY.RU journals that investigated the role of the autonomic nervous system in chronic heart failure. The article discusses the origins of heart rate variability assessment and diagnostic tools for evaluating autonomic nervous system function in various cardiovascular diseases. The review describes the pathogenetic mechanisms underlying changes in autonomic status and the key parameters used to assess it, predominantly based on noninvasive time- and frequency-domain heart rate variability analysis for a more accurate evaluation of adaptation level, stress reactivity, and the degree of autonomic imbalance. Data on age- and sex-related differences in heart rate variability in patients with chronic heart failure are presented, including those with comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, and diabetes mellitus. Evidence is provided to support the prognostic value of heart rate variability parameters that influence disease course and cardiovascular risk in patients with chronic heart failure. Investigating the pathogenetic mechanisms underlying autonomic dysfunction in patients with cardiovascular diseases is relevant for developing new therapeutic approaches to restore autonomic nervous system balance. Time- and frequency-domain heart rate variability analysis is an accessible and convenient noninvasive method that can be used in a wide patient population to provide valuable information for personalized therapeutic strategies.
- Open Access
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 64-69
Heart failure in Duchenne's progressive muscular dystrophy (case report)
Progressive Duchenne muscular dystrophy is a common X-linked recessive myopathy caused by a mutations in the gene encoding dystrophin. Duchenne muscular dystrophy is characterized by damage to the heart muscle with conduction and rhythm disturbances, and the development of dilated cardiomyopathy, which may be asymptomatic. The development of heart failure determines the unfavorable prognosis of patients with Duchenne muscular dystrophy. Insufficient awareness of physicians about the characteristics of heart damage in Duchenne muscular dystrophy creates the prerequisites for describing interesting clinical observations. The article presents a clinical observation of the development of dilated cardiomyopathy and heart failure with a low left ventricular ejection fraction in a 19-year-old male patient with Duchenne muscular dystrophy. The dynamics of Duchenne muscular dystrophy progression from the moment of diagnosis to the development of decompensated heart failure are described. The article presents clinical course data, laboratory parameters, electrocardiography and echocardiography data in dynamics. The article presents diagnostic criteria for Duchenne muscular dystrophy, prospects for therapy aimed at correcting the genetic defect by replacing, modifying or reparating the dystrophin gene. The presented case demonstrates the need for a personalized multidisciplinary approach to a patient with Duchenne muscular dystrophy, with the participation of an orthopedic surgeon, pulmonologist, cardiologist, endocrinologist, and ophthalmologist.
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 64-69
Open AccessHeart failure in Duchenne's progressive muscular dystrophy (case report)
Progressive Duchenne muscular dystrophy is a common X-linked recessive myopathy caused by a mutations in the gene encoding dystrophin. Duchenne muscular dystrophy is characterized by damage to the heart muscle with conduction and rhythm disturbances, and the development of dilated cardiomyopathy, which may be asymptomatic. The development of heart failure determines the unfavorable prognosis of patients with Duchenne muscular dystrophy. Insufficient awareness of physicians about the characteristics of heart damage in Duchenne muscular dystrophy creates the prerequisites for describing interesting clinical observations. The article presents a clinical observation of the development of dilated cardiomyopathy and heart failure with a low left ventricular ejection fraction in a 19-year-old male patient with Duchenne muscular dystrophy. The dynamics of Duchenne muscular dystrophy progression from the moment of diagnosis to the development of decompensated heart failure are described. The article presents clinical course data, laboratory parameters, electrocardiography and echocardiography data in dynamics. The article presents diagnostic criteria for Duchenne muscular dystrophy, prospects for therapy aimed at correcting the genetic defect by replacing, modifying or reparating the dystrophin gene. The presented case demonstrates the need for a personalized multidisciplinary approach to a patient with Duchenne muscular dystrophy, with the participation of an orthopedic surgeon, pulmonologist, cardiologist, endocrinologist, and ophthalmologist.
- Open Access
- 25 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 810-818
Cardiovascular diseases and personality type
Cardiovascular diseases are a leading cause of death, especially in developed countries. As new evidence-based medical findings emerge, the range of risk factors for cardiovascular diseases expands. Modern cardiology acknowledges that the development of a cardiovascular risk management system is critical. Psychological aspects, including personality, emotional regulation, and associated behaviors, have been found to contribute to cardiovascular disease onset and progression. This review summarizes and systematizes information from clinical studies and systematic reviews published through PubMed and eLIBRARY.RU. These databases were searched for articles detailing how personality types may influence the clinical course and prognosis of cardiovascular diseases through the interplay with various biological and behavioral factors. Moreover, this study provides an overview of personality types A, B, AB, and D and the methods for their identification. These methods include the Jenkins and Wasserman–Gumenyuk questionnaires, which were adapted for the Russian-speaking population to align with the cultural context, focusing on identifying personality type D (DS-14). Enhancing medical professionals’ awareness of personality traits and their role in cardiovascular diseases can facilitate deeper understanding of the causes of patient maladaptation and improve the effectiveness of strategies for preventing complications. Targeted and prompt psychotherapeutic interventions will contribute to the modification of negative aspects, decrease cardiovascular event risk, increase treatment compliance, and increase life expectancy.
- 25 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 810-818
Open AccessCardiovascular diseases and personality type
Cardiovascular diseases are a leading cause of death, especially in developed countries. As new evidence-based medical findings emerge, the range of risk factors for cardiovascular diseases expands. Modern cardiology acknowledges that the development of a cardiovascular risk management system is critical. Psychological aspects, including personality, emotional regulation, and associated behaviors, have been found to contribute to cardiovascular disease onset and progression. This review summarizes and systematizes information from clinical studies and systematic reviews published through PubMed and eLIBRARY.RU. These databases were searched for articles detailing how personality types may influence the clinical course and prognosis of cardiovascular diseases through the interplay with various biological and behavioral factors. Moreover, this study provides an overview of personality types A, B, AB, and D and the methods for their identification. These methods include the Jenkins and Wasserman–Gumenyuk questionnaires, which were adapted for the Russian-speaking population to align with the cultural context, focusing on identifying personality type D (DS-14). Enhancing medical professionals’ awareness of personality traits and their role in cardiovascular diseases can facilitate deeper understanding of the causes of patient maladaptation and improve the effectiveness of strategies for preventing complications. Targeted and prompt psychotherapeutic interventions will contribute to the modification of negative aspects, decrease cardiovascular event risk, increase treatment compliance, and increase life expectancy.
- 10 March 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 102 (11-12)
Trajectories of long-term outcome of heart failure with concomitant chronic kidney disease: the significance of high-sensitivity C-reactive protein
Inflammation is intimately associated with atherosclerotic disease, including in patients with chronic heart failure (CHF), and high-sensitivity C-reactive protein (hsCRP) levels play a key role in determining severity and outcome.Objective: to study the potential of serum hsCRP for predicting the outcome of ischemic heart failure in the presence of chronic kidney disease (CKD).Material and methods. Clinical signs and 5-year outcomes of patients with CHF (n = 517), including those in combination with CKD (n = 207), were studied.Results and conclusions. The phenotype of CHF in combination with CKD was characterized by female gender, older age, a higher prevalence of arterial hypertension, diabetes mellitus, previous myocardial infarction and coronary intervention, lower cardiorespiratory endurance, higher levels of hsCRP (p = 0.005), low-density lipoprotein cholesterol (p = 0.021), non-high-density lipoprotein cholesterol (p = 0.015). Patients with CHF with hsCRP > 3 mg/L have a higher 5-year risk of death from any cause, cardiovascular death, and achieving the composite endpoint (CCT). An increase in hsCRP for every 1 mg/l in CHF increases the risk of death from all causes (HR = 1.1; 95% CI 0.99–1.21), cardiovascular death (HR = 1.11; 95% CI 1.01–1.23). Death from any cause and cardiovascular death with CHF, incl. in the presence of CKD, hsCRP > 3.07 mg/l was predicted. Achieving CCT was predicted in patients with CHF with hsCRP > 2.69 mg/l, in patients with a combination of CHF and CKD — with hsCRP > 2.5 mg/l.
- 10 March 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 102 (11-12)
Trajectories of long-term outcome of heart failure with concomitant chronic kidney disease: the significance of high-sensitivity C-reactive protein
Inflammation is intimately associated with atherosclerotic disease, including in patients with chronic heart failure (CHF), and high-sensitivity C-reactive protein (hsCRP) levels play a key role in determining severity and outcome.Objective: to study the potential of serum hsCRP for predicting the outcome of ischemic heart failure in the presence of chronic kidney disease (CKD).Material and methods. Clinical signs and 5-year outcomes of patients with CHF (n = 517), including those in combination with CKD (n = 207), were studied.Results and conclusions. The phenotype of CHF in combination with CKD was characterized by female gender, older age, a higher prevalence of arterial hypertension, diabetes mellitus, previous myocardial infarction and coronary intervention, lower cardiorespiratory endurance, higher levels of hsCRP (p = 0.005), low-density lipoprotein cholesterol (p = 0.021), non-high-density lipoprotein cholesterol (p = 0.015). Patients with CHF with hsCRP > 3 mg/L have a higher 5-year risk of death from any cause, cardiovascular death, and achieving the composite endpoint (CCT). An increase in hsCRP for every 1 mg/l in CHF increases the risk of death from all causes (HR = 1.1; 95% CI 0.99–1.21), cardiovascular death (HR = 1.11; 95% CI 1.01–1.23). Death from any cause and cardiovascular death with CHF, incl. in the presence of CKD, hsCRP > 3.07 mg/l was predicted. Achieving CCT was predicted in patients with CHF with hsCRP > 2.69 mg/l, in patients with a combination of CHF and CKD — with hsCRP > 2.5 mg/l.
- 2 October 2024
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 105 (5) , 750-759
Gender and age clinical characteristics of patients with acute coronary syndrome
Cardiovascular diseases remain a common cause of morbidity and mortality in populations around the world, varying in incidence by age and gender. Every year, more than 7 million people around the world are diagnosed with acute coronary syndrome, which may be the first clinical manifestation of coronary heart disease. In the ranking of mortality causes in the Russian Federation, diseases of the circulatory system occupy a leading place. The purpose of the review was to analyze the clinical characteristics and spectrum of coronary lesions of patients with acute coronary syndrome depending on age and gender. Thus, according to the results of coronary angiography, young patients with myocardial infarction were rarely accompanied by multivessel or ostial lesions of the coronary arteries, in contrast to the elderly patients. It was revealed that multivessel lesions of the coronary arteries more often characterize males, and singlevessel lesions more often characterize females. It is obvious that the prognosis of patients with acute coronary syndrome will largely depend not only on age and gender, but also on the outcome of the syndrome, the quality and scope of diagnostic and treatment procedures. This is especially important since most patients under 60 years of age are exposed to some form of systematic work load in their field of activity. The influence of polypathy, characteristic of modern cardiac patients, can be expressed to varying degrees depending on the gender and age of the patient with acute coronary syndrome. The article presents data on the short-term and long-term prognosis of patients with acute coronary syndrome, taking into account gender and age periods, including depending on the tactics of their management. Determining the clinical characteristics of patients of different ages allows to take them into account for selecting effective and safe therapy, preventing wave-like atherosclerosis as the main cause of coronary heart disease, thereby improving prognosis and survival.
- 2 October 2024
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 105 (5) , 750-759
Gender and age clinical characteristics of patients with acute coronary syndrome
Cardiovascular diseases remain a common cause of morbidity and mortality in populations around the world, varying in incidence by age and gender. Every year, more than 7 million people around the world are diagnosed with acute coronary syndrome, which may be the first clinical manifestation of coronary heart disease. In the ranking of mortality causes in the Russian Federation, diseases of the circulatory system occupy a leading place. The purpose of the review was to analyze the clinical characteristics and spectrum of coronary lesions of patients with acute coronary syndrome depending on age and gender. Thus, according to the results of coronary angiography, young patients with myocardial infarction were rarely accompanied by multivessel or ostial lesions of the coronary arteries, in contrast to the elderly patients. It was revealed that multivessel lesions of the coronary arteries more often characterize males, and singlevessel lesions more often characterize females. It is obvious that the prognosis of patients with acute coronary syndrome will largely depend not only on age and gender, but also on the outcome of the syndrome, the quality and scope of diagnostic and treatment procedures. This is especially important since most patients under 60 years of age are exposed to some form of systematic work load in their field of activity. The influence of polypathy, characteristic of modern cardiac patients, can be expressed to varying degrees depending on the gender and age of the patient with acute coronary syndrome. The article presents data on the short-term and long-term prognosis of patients with acute coronary syndrome, taking into account gender and age periods, including depending on the tactics of their management. Determining the clinical characteristics of patients of different ages allows to take them into account for selecting effective and safe therapy, preventing wave-like atherosclerosis as the main cause of coronary heart disease, thereby improving prognosis and survival.
- Open Access
- 25 July 2024
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 105 (4) , 567-577
Comorbidity of chronic heart failure of ischemic etiology and chronic obstructive pulmonary disease: 5-year follow-up
BACKGROUND: The combination of chronic heart failure and chronic obstructive pulmonary disease contributes to the formation of the phenotype and survival of patients. AIM: To study the 5-year prognosis and develop a prognostic model of adverse events in patients with chronic heart failure of ischemic origin in comorbidity with chronic obstructive pulmonary disease. MATERIAL AND METHODS: Clinical signs of patients with chronic heart failure of ischemic origin (n=517), including those in combination with chronic obstructive pulmonary disease (n=118), and outcomes over 5 years according to end points: death from all causes, cardiovascular death, composite endpoint — all fatal and non-fatal cardiovascular events, were studied. Quantitative variables were presented as mean and standard deviation or median and interquartile range; categorical — in the form of absolute value and percentage. Quantitative intergroup differences were assessed using the Mann–Whitney test, and categorical differences were assessed using the Pearson χ2 test. Time to event was analyzed using the Kaplan–Meier method; hazard ratio — by Cox regression. Models were developed using binary logistic regression. Statistical processing was carried out in the Jamovi, R 4.3.1 programs. RESULTS: The clinical portrait of a patient with chronic heart failure of ischemic origin in the presence of chronic obstructive pulmonary disease was characterized by a predominance of men in older age groups, a high frequency of smoking, a worse quality of life, determined by the Minnesota Questionnaire, and a high level of high-sensitivity C-reactive protein, α1- and α2-globulins. Patients with heart failure in the presence of chronic obstructive pulmonary disease had higher overall and cardiovascular mortality (p=0.029 and p=0.02), the frequency of hospitalizations not related to cardiovascular disease (p=0.02), less non-fatal cardiovascular events (p=0.04). CONCLUSION: In patients with heart failure, the presence of chronic obstructive pulmonary disease increased the risk of death from all causes by 2.07 times, cardiovascular mortality by 2.24 times, and achieving the combined endpoint by 1.68 times. Regression models were developed to determine the probability of risk of death from all causes and cardiovascular death.
- 25 July 2024
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 105 (4) , 567-577
Open AccessComorbidity of chronic heart failure of ischemic etiology and chronic obstructive pulmonary disease: 5-year follow-up
BACKGROUND: The combination of chronic heart failure and chronic obstructive pulmonary disease contributes to the formation of the phenotype and survival of patients. AIM: To study the 5-year prognosis and develop a prognostic model of adverse events in patients with chronic heart failure of ischemic origin in comorbidity with chronic obstructive pulmonary disease. MATERIAL AND METHODS: Clinical signs of patients with chronic heart failure of ischemic origin (n=517), including those in combination with chronic obstructive pulmonary disease (n=118), and outcomes over 5 years according to end points: death from all causes, cardiovascular death, composite endpoint — all fatal and non-fatal cardiovascular events, were studied. Quantitative variables were presented as mean and standard deviation or median and interquartile range; categorical — in the form of absolute value and percentage. Quantitative intergroup differences were assessed using the Mann–Whitney test, and categorical differences were assessed using the Pearson χ2 test. Time to event was analyzed using the Kaplan–Meier method; hazard ratio — by Cox regression. Models were developed using binary logistic regression. Statistical processing was carried out in the Jamovi, R 4.3.1 programs. RESULTS: The clinical portrait of a patient with chronic heart failure of ischemic origin in the presence of chronic obstructive pulmonary disease was characterized by a predominance of men in older age groups, a high frequency of smoking, a worse quality of life, determined by the Minnesota Questionnaire, and a high level of high-sensitivity C-reactive protein, α1- and α2-globulins. Patients with heart failure in the presence of chronic obstructive pulmonary disease had higher overall and cardiovascular mortality (p=0.029 and p=0.02), the frequency of hospitalizations not related to cardiovascular disease (p=0.02), less non-fatal cardiovascular events (p=0.04). CONCLUSION: In patients with heart failure, the presence of chronic obstructive pulmonary disease increased the risk of death from all causes by 2.07 times, cardiovascular mortality by 2.24 times, and achieving the combined endpoint by 1.68 times. Regression models were developed to determine the probability of risk of death from all causes and cardiovascular death.
- Open Access
- 22 November 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 64-68
Interleukin-1β gene rs1143634 polymorphism and cardiovascular complications in patients with coronary artery atherosclerosis
The course of heart failure, regardless of its etiology, is associated with local and systemic activation of inflammatory signaling cascades. Identification of the association of candidate cytokine genes with the risk of developing coronary heart disease and chronic heart failure remains a subject of interest for many researchers. The review presents an analysis of studies of the rs1143634 polymorphism of the IL-β gene in relation to the risk of atherosclerotic cardiovascular complications. The presence of the minor allele T is associated with an increase in the concentration of IL-1β in the blood serum. Data on the role of the rs1143634 polymorphism of the IL-β gene in atherosclerotic coronary heart disease, including in combination with chronic heart failure syndrome, are presented, taking into account ethnic characteristics and gender of patients. The carriage of the T allele was associated with the risk of developing atherosclerosis and myocardial infarction. At the same time, it is reported that the C allele and the CC genotype of the rs1143634 polymorphism of the IL-1β gene were a genetic risk factor for the development and progression of heart failure. In a number of studies and meta-analyses, the association of this polymorphism with diseases of the cardiovascular system was not confirmed, but certain trajectories of the risk of complications were identified due to differences in the rs1143634 polymorphism of the IL-β gene in heart failure.
- 22 November 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 64-68
Open AccessInterleukin-1β gene rs1143634 polymorphism and cardiovascular complications in patients with coronary artery atherosclerosis
The course of heart failure, regardless of its etiology, is associated with local and systemic activation of inflammatory signaling cascades. Identification of the association of candidate cytokine genes with the risk of developing coronary heart disease and chronic heart failure remains a subject of interest for many researchers. The review presents an analysis of studies of the rs1143634 polymorphism of the IL-β gene in relation to the risk of atherosclerotic cardiovascular complications. The presence of the minor allele T is associated with an increase in the concentration of IL-1β in the blood serum. Data on the role of the rs1143634 polymorphism of the IL-β gene in atherosclerotic coronary heart disease, including in combination with chronic heart failure syndrome, are presented, taking into account ethnic characteristics and gender of patients. The carriage of the T allele was associated with the risk of developing atherosclerosis and myocardial infarction. At the same time, it is reported that the C allele and the CC genotype of the rs1143634 polymorphism of the IL-1β gene were a genetic risk factor for the development and progression of heart failure. In a number of studies and meta-analyses, the association of this polymorphism with diseases of the cardiovascular system was not confirmed, but certain trajectories of the risk of complications were identified due to differences in the rs1143634 polymorphism of the IL-β gene in heart failure.
- Open Access
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 674-678
Tumor necrosis factor gene polymorphism rs1800629 in patients with atherosclerotic cardiovascular diseases: A review
The close attention of researchers is riveted to the study of socially significant multifactorial diseases and syndromes with a hereditary predisposition, which include chronic heart failure, formed as a result of atherosclerosis of the coronary arteries. The promise of genomic studies in atherosclerosis and heart failure is associated with the possibility of determining the genetic risk of developing and predicting adverse cardiovascular events before the onset of clinical signs/symptoms. From the standpoint of understanding the pathogenesis of atherosclerosis as a variant of nonspecific inflammation, which has a wave-like character, it is assumed that genes encoding pro-inflammatory cytokines influence the pathological process. The aim of the review was to analyze the results of studies available in available publications on the rs1800629 polymorphism of the tumor necrosis factor (TNF) gene in patients with atherosclerotic cardiovascular diseases. Most data indicate the presence of an increased cardiovascular risk in carriers of the A allele of the rs1800629 polymorphism of the TNF gene. It was determined that carriage of the AA genotype is associated with essential arterial hypertension and remodeling of the left ventricular myocardium. In patients with chronic heart failure with preserved and moderately reduced left ventricular ejection fraction of the AA genotype, low blood pressure and frequent occurrence of atrial fibrillation were noted. A number of papers present the results of studies of the rs1800629 polymorphism of the TNF gene and the prognostic significance of the rs1800629 polymorphism of the TNF gene in heart failure.
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 674-678
Open AccessTumor necrosis factor gene polymorphism rs1800629 in patients with atherosclerotic cardiovascular diseases: A review
The close attention of researchers is riveted to the study of socially significant multifactorial diseases and syndromes with a hereditary predisposition, which include chronic heart failure, formed as a result of atherosclerosis of the coronary arteries. The promise of genomic studies in atherosclerosis and heart failure is associated with the possibility of determining the genetic risk of developing and predicting adverse cardiovascular events before the onset of clinical signs/symptoms. From the standpoint of understanding the pathogenesis of atherosclerosis as a variant of nonspecific inflammation, which has a wave-like character, it is assumed that genes encoding pro-inflammatory cytokines influence the pathological process. The aim of the review was to analyze the results of studies available in available publications on the rs1800629 polymorphism of the tumor necrosis factor (TNF) gene in patients with atherosclerotic cardiovascular diseases. Most data indicate the presence of an increased cardiovascular risk in carriers of the A allele of the rs1800629 polymorphism of the TNF gene. It was determined that carriage of the AA genotype is associated with essential arterial hypertension and remodeling of the left ventricular myocardium. In patients with chronic heart failure with preserved and moderately reduced left ventricular ejection fraction of the AA genotype, low blood pressure and frequent occurrence of atrial fibrillation were noted. A number of papers present the results of studies of the rs1800629 polymorphism of the TNF gene and the prognostic significance of the rs1800629 polymorphism of the TNF gene in heart failure.
- Open Access
- 6 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (1) , 3382
Residual risk in patients with atherosclerotic cardiovascular disease
The residual risk in patients with atherosclerosis, despite the its controversial aspects, remains an urgent problem of modern cardiology. The article presents a review of publications on the prevalence and significance for determining the prognosis of residual risk, which is currently interpreted as the risk of macroand microvascular complications in patients with atherosclerotic cardiovascular disease (ACVD) taking standard therapy, with the achievement of optimal levels of low-density lipoprotein cholesterol, blood pressure and glucose. Based on available publications, we highlighted current views on the factors associated with residual inflammatory and lipid risks in ACVD patients, including those associated with heart failure and diabetes, and the prognostic significance of residual risk in such patients. An attempt was made to rationale the significance of determining the residual risk for secondary prevention of cardiovascular events.
- 6 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (1) , 3382
Open AccessResidual risk in patients with atherosclerotic cardiovascular disease
The residual risk in patients with atherosclerosis, despite the its controversial aspects, remains an urgent problem of modern cardiology. The article presents a review of publications on the prevalence and significance for determining the prognosis of residual risk, which is currently interpreted as the risk of macroand microvascular complications in patients with atherosclerotic cardiovascular disease (ACVD) taking standard therapy, with the achievement of optimal levels of low-density lipoprotein cholesterol, blood pressure and glucose. Based on available publications, we highlighted current views on the factors associated with residual inflammatory and lipid risks in ACVD patients, including those associated with heart failure and diabetes, and the prognostic significance of residual risk in such patients. An attempt was made to rationale the significance of determining the residual risk for secondary prevention of cardiovascular events.